Recruiting studies: Hemophilia B Severe

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265)
Phase 1/Phase 2 · 44 location(s) · Regeneron Pharmaceuticals · NCT06379789 Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Ade
Phase 3 · 30 location(s) · CSL Behring · NCT06003387 Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or
Phase 3 · 12 location(s) · CSL Behring · NCT07080905 Liver Biopsy In Haemophilia Gene Therapy
NA · 1 location(s) · University College, London · NCT04817462 A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Phase 3 · 34 location(s) · Pfizer · NCT05611801 Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Phase 3 · 75 location(s) · Pfizer · NCT05145127

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.